Microglia May Drive Alzheimer’s Plaque Formation, Study Finds

The brain’s immune system, long considered a defender against Alzheimer’s disease, may surprisingly play a role in building the hallmarks of the condition – the amyloid plaques that disrupt brain function. A new study from researchers at VIB and KU Leuven challenges the conventional understanding of microglia, the brain’s resident immune cells and their relationship to plaque formation. The findings, published in the Proceedings of the National Academy of Sciences, suggest that microglia can actively contribute to the aggregation of amyloid-β, the protein fragment that forms these plaques.

Microglia: From Protectors to Potential Contributors

For years, microglia have been viewed as the brain’s cleanup crew, tasked with removing debris and misfolded proteins, including amyloid-β. This protective role led researchers to believe that activating microglia would be a promising therapeutic strategy for Alzheimer’s disease. However, the new research suggests a more nuanced picture. The study indicates that under certain conditions, microglia can actually promote the clumping of amyloid-β, accelerating plaque formation.

This isn’t to say microglia are inherently “disappointing.” Their function is complex, and their response to amyloid-β appears to change as the disease progresses. The VIB-KU Leuven team’s work focuses on understanding these dynamic interactions at a molecular level. Researchers are investigating the influence of astrocytes – another type of brain cell – on these processes, particularly at the early stages of the disease. The Laboratory for the Research of Neurodegenerative Diseases at KU Leuven is actively pursuing several projects focused on unraveling these cellular interactions.

Unpacking the Study: Methods and Limitations

The study’s findings are based on laboratory research, primarily using mouse models of Alzheimer’s disease. While these models are valuable tools for studying the disease, it’s crucial to remember that they don’t perfectly replicate the complexity of the human condition. The researchers examined how microglia interact with amyloid-β in the brain and identified specific mechanisms by which they can promote its aggregation.

It’s important to note that the study doesn’t definitively prove that microglia cause Alzheimer’s disease. It demonstrates a correlation – a link – between microglial activity and plaque formation. Establishing causation would require further research, including studies in human brain tissue. The research also doesn’t fully explain why microglia sometimes promote plaque formation, opening avenues for future investigation.

Familial Alzheimer’s and the Role of Genetic Mutations

Understanding the genetic underpinnings of Alzheimer’s disease is a key area of research. A separate study, conducted by researchers at VIB-KU Leuven and published in Molecular Neurodegeneration in May 2025, has made progress in predicting the onset of familial Alzheimer’s disease. This research, led by Prof. Lucía Chávez Gutiérrez, revealed how specific genetic mutations act as a “clock” to predict when the disease will develop in individuals with a family history of the condition.

Familial Alzheimer’s, while rare, is caused by mutations in genes involved in the processing of amyloid precursor protein (APP), Presenilin 1 (PSEN1), or Presenilin 2 (PSEN2). The new model developed by Prof. Chávez Gutiérrez’s team could aid clinicians in providing more accurate diagnoses and tailoring treatment strategies for these patients. This work complements the microglia research by highlighting the complex interplay between genetic predisposition and cellular mechanisms in Alzheimer’s disease.

What Does This Mean for Alzheimer’s Research?

The finding that microglia can contribute to plaque formation doesn’t negate the importance of the brain’s immune system in Alzheimer’s disease. Instead, it suggests that therapeutic strategies need to be more targeted. Simply activating microglia may not be enough – and could even be detrimental – if it inadvertently promotes amyloid-β aggregation.

Researchers are now exploring ways to modulate microglial activity, shifting them from a pro-plaque state to a protective one. This could involve identifying specific molecules that trigger the harmful response or developing therapies that selectively enhance the microglia’s ability to clear amyloid-β. The VIB-KU Leuven Center for Neuroscience is actively engaged in this type of research, utilizing single-cell and genome-wide analysis to understand the complex cellular changes that occur in Alzheimer’s disease.

Beyond Plaques: A Holistic View of Alzheimer’s

It’s crucial to remember that amyloid plaques are just one piece of the Alzheimer’s puzzle. The disease is characterized by a complex interplay of factors, including the accumulation of tau protein, inflammation, and neuronal loss. Researchers are increasingly recognizing the importance of considering these factors together, rather than focusing solely on amyloid-β.

The Laboratory for the Research of Neurodegenerative Diseases is also investigating the link between tau pathology, granulovacuolar neurodegeneration, and necroptosis – a form of programmed cell death – in Alzheimer’s disease. This broader approach is essential for developing effective treatments that address the multiple facets of the disease.

What Comes Next: Refining Therapeutic Approaches

The current research underscores the need for a more refined understanding of the brain’s immune response in Alzheimer’s disease. Future studies will focus on identifying the specific triggers that cause microglia to switch from a protective to a harmful state. Researchers will also explore the potential of using biomarkers – measurable indicators of disease – to identify individuals who are at risk of developing Alzheimer’s and to monitor the effectiveness of new therapies. Clinical trials are ongoing to test various approaches to modulating microglial activity and targeting amyloid-β. The results of these trials will be crucial for determining the best way to translate these research findings into clinical practice.